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Abstract
Background: Obstructive sleep apnea (OSA) often occurs in patients 
with active acromegaly and improves after treatment. Less is known 
about the development of OSA in patients after a longer period of 
control treated with somatostatin analogues (SSA) and pegvisomant.
Methods: Seventy-nine patients (12 females, 17 males; age 49 ± 14 
years; body mass index 29.9 ± 5.4 kg/m2; IGF-1 184 ± 73 µg/L; dis-
ease duration 13 ± 8 years (mean ± standard deviation)) with well-
controlled acromegaly treated with SSA (38%), pegvisomant (38%) 
or in combination (24%) who underwent ambulatory polygraphy 
were included in a prospective multicenter cross-sectional study.
Results: Fourteen percent had OSA (range of apnea-hypopnea index 
(AHI) 5 - 15). Patients with OSA (AHI ≥ 5 vs. < 5) had a longer dis-
ease duration (16 ± 1 vs. 12 ± 8 years; P = 0.01) and were older (61 ± 
9 vs. 47 ± 13 years; P = 0.037). The AHI of all patients correlated with 
age (P = 0.01; r = 0.44). No differences were seen in terms of BMI 
and Epworth sleepiness scale score. Previous transsphenoidal surgery 
and radiation had no impact of the detection of OSA. The duration of 
well-controlled acromegaly was 7 ± 3 years.
Conclusion: OSA in patients with well-controlled acromegaly treated 
with SSA, pegvisomant or in combination is less frequent (14%) than 
previously described. Early treatment to reduce the active disease pe-
riod should be aimed to prevent OSA.
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Introduction
Obstructive sleep apnea (OSA) is one of several systemic com-
plications in patients with acromegaly [1]. Soft tissue swelling 
of the uvula, enlargement of the tongue and prognathism due 
to the mandibular growth are clinical manifestations of the pe-
riod of active disease and characterize the OSA which is most 
prevalent in acromegaly [2-5]. Central apnea is infrequent and 
is associated with high endogenous somatostatin tonus [6, 7].
It has been shown that 50-87% of patients with active 
disease have OSA [2]. After sufficient treatment with soma-
tostatin analogues (SSA), pegvisomant or successful resection 
of the GH-producing adenoma after transsphenoidal surgery, 
parameters and prevalence of OSA significantly reduced [3, 8].
Beside the fact of high prevalence of OSA in patients with 
acromegaly, OSA is diagnosed in up to 2-5% of the general 
population and hence not a rare disease [9]. In this group, OSA 
is associated with age, body mass index (BMI) and hyper-
tension. Less is known about the prevalence of sleep apnea 
syndrome in patients with well-controlled acromegaly after a 
longer period of time. It was mentioned in previous papers that 
a longer follow-up to detect later potential improvements in 
OSA will be needed [10, 11]. Therefore, we initiated a mul-
ticenter study to evaluate clinical manifestations via Epworth 
sleepiness scale score and ambulatory polygraphy in patients 
with well-controlled acromegaly treated with SSA, pegviso-
mant or in combination.
Patients and Methods
Patients
Twenty-nine patients (12 females and 17 males) with a mean 
age of 49 ± 14 years (range 25 - 73 years) and BMI of 29.9 ± 
5.4 kg/m2 (range 20.8 - 29.9 kg/m2) with well-controlled ac-
romegaly (IGF-I 184 ± 73 µg/L (range 74 - 383 µg/L); SSA 
(38%), pegvisomant (38%) or in combination (24%)) were in-
cluded in the cross-sectional prospective multicenter study of 
eight Departments of Endocrinology in Germany. Eleven pa-
tients were treated with pegvisomant (10/11 10 - 40 mg daily, 
1/11 with 30 mg weekly), six patients with octreotide (10 - 30 
mg every 4 weeks), five patients with lanreotide (60 - 120 mg 
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every 4 - 8 weeks), four patients with pegvisomant (10 - 30 
mg daily) in combination with lanreotide (60 - 120 mg every 
4 - 8 weeks) and three patients with pegvisomant (20 - 30 mg 
daily) in combination with octreotide (30 mg every 4 weeks). 
Thirty-four percent of patients had hypertension, 3% diabetes 
mellitus and 14% both. Twenty-four percent had ACTH defi-
ciency, 41% TSH deficiency, and 7% diabetes insipidus (Table 
1). Seventy-six percent underwent previous surgery and 24% 
surgery and radiation.
The disease duration was estimated from the lag time be-
tween the onset of symptoms and signs of disease and the date 
when the treatment was proven to be effective (well-controlled 
patients). Moreover, the disease duration was assumed to be 
the interval between the clinical onset determined by compari-
son of old photographs and the time of treatment. The dura-
tion of well-controlled acromegaly was 7 ± 3 years (range 2 
- 11 years). Daytime sleepiness was assessed by the Epworth 
sleepiness questionnaire.
Ambulatory polygraphy
Ambulatory polygraphy using the Somno-Check (Weinmann 
Medical Technology, GmbH, Hamburg, Germany) was per-
formed between 10 pm and 7 am. Oronasal airflow was record-
ed by thermistor; thoracic and abdominal respiratory efforts 
were measured by impedance plethysmography. Oxygen satu-
ration was measured by finger pulse oximetry (ResMed Model 
305A, San Diego, CA, USA). Body position was monitored by 
a position sensor. Patients had been instructed to behave dur-
ing the night as “normally” as possible.
Apnea was defined as cessation of airflow or reduction in 
thermistor signal to less than 10% of the normal flow and last-
ing for at least 10 s. Apneas shorter than 10 s were counted if 
they were followed by an oxygen desaturation of 4% or more. 
Events were classified as obstructive (clear obstructive or 
mixed with a clear obstructive component in the event) accord-
ing to the respiratory effort channels. Hyponea was defined as 
a discernible reduction in airflow of at least 10 s duration fol-
lowed by a desaturation of 4% or more.
The respiratory events were scored in accordance to the 
American Academy of Sleep Medicine Task Force recommen-
dations [12]. The apnea-hypopnea index (AHI) was calculat-
ed as the number of all respiratory events per hour of sleep. 
An AHI shorter than 5 was defined as normal. Sleep-related 
breathing events were considered mild when AHI was between 
5 and 15 events per hour, moderate in cases of AHI between 
15 and 30 events per hour and severe if AHI was greater than 
30 events per hour. Clear oxygen saturation (SaO2) artifacts 
were excluded manually. Oxygen indices were then calculated 
by the software from the SaO2 curve with minimal SaO2 being 
the lowest saturation reached during sleep and with average 
minimal SaO2 being the mean of all saturation values reached 
during all respiratory events.
Determination of serum IGF-I concentrations
IGF-I concentrations were measured centrally using the iSYS 
automated chemiluminescent IGF-I assay (Immunodiagnostic 
Systems (IDS) Ltd, Boldon, England, UK). The assay employs 
two monoclonal antibodies and is calibrated against the WHO 
International Standard 02/254 (National Institute for Biologi-
cal Standards (NIBSC), Hertfordshire, UK). On board acidi-
fication of samples to separate IGF-I from its binding protein 
IGFBP 3 is followed by incubation in the presence of excess 
IGF-II to prevent re-aggregation. No interference or cross-re-
activity was observed with IGF-II, insulin, proinsulin and the 
six high affinity IGFBPs. In our hands, intra-assay CVs were 
between 1.1% and 2.0% at concentrations between 87 and 733 
ng/mL, whereas inter-assay CVs ranged from 2.7% to 10.0% 
at concentrations between 68 and 490 ng/mL. The lower limit 
of quantification was 10 ng/mL, and the linear range was 10 - 
1,200 ng/mL. Up to five freeze/thaw cycles had no detectable 
influence on measured concentrations. Results of the partici-
pants were compared to extensive method specific reference 
intervals stratified for age and sex [13].
Statistical analyses
The data, if not marked otherwise, represent the mean ± stand-
ard deviation. Differences between two groups were tested by 
Mann-Whitney U-test as a non-parametric procedure. All tests 
were done two-tailed, and P-values < 0.05 were considered 
statistically significant. Statistical analyses were performed 
using GraphPad InStat version 3.02 (GraphPad Software, San 
Diego, CA, USA).
Ethics
The trial was conducted in accordance with the Declaration 
of Helsinki for biomedical research involving human subjects. 
The study protocol has to be approved by the ethics commit-
tee of the medical association of Westfalia-Lippe, Muenster, 
Germany.
Table 1.  Patients With Well-Controlled Acromegaly Treated 
With Somatostatin Analogues, Pegvisomant or in Combination 





Age (years) 49 ± 14 25 - 73
BMI (kg/m2) 29.9 ± 5.4 20.8 - 29.9
Disease duration (years) 13 ± 8 2 - 32
IGF-I (µg/L) 184 ± 73 74 - 383
Well-controlled acromegaly 29 (100%)
Surgery 22 (76%)
Radiation + surgery 7 (24%)
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Results
Fourteen percent (4/29) had a mild OSA (range of AHI 5 - 15). 
One patient had an AHI of 5, two 7 and one 15. Patients with 
an AHI ≥ 5 had a longer disease duration than patients with 
AHI < 5 (16 ± 1 vs. 12 ± 8 years, P = 0.01, Fig. 1). Age, BMI 
and the score of the Epworth sleepiness scale were similar in 
both groups (Table 2). The mean score of the Epworth sleepi-
ness scale of all patients was 5.4 ± 3.5. Age correlated with 
AHI (P = 0.01, r = 0.44, Fig. 2), but BMI did not correlate with 
AHI. Previous and current treatment of the two groups did not 
differ significantly (Table 3). The prevalence values of hyper-
tension and diabetes mellitus were similar in both groups (2/4 
patients in group AHI ≥ 5: one hypertension and one hyperten-
sion in combination with diabetes mellitus; 13/25 patients in 
the group AHI < 5: nine hypertension, one diabetes mellitus 
and three hypertension in combination with diabetes mellitus).
Discussion
In the present study, it has been shown that patients with well-
controlled acromegaly treated with SSA, pegvisomant or in 
combination had a low frequency (14%) of OSA.
In patients with active acromegaly, prevalence of sleep 
apnea varies between 50% and 87% [2]. This high range may 
be due to the different age, BMI and disease duration of the 
cohorts [14]. Moreover, it has to be considered that sleep apnea 
can be examined with different procedures: ambulatory pol-
ygraphy versus inpatient polysomnography. Furthermore, high 
prevalence of sleep apnea can be influenced by preselectional 
bias, if e.g. symptoms and signs of sleep apnea (high Epworth 
sleepiness scale) are preconditions for polysomnography.
Successful treatments by surgery and with SSA, pegvi-
somant or in combination improved sleep apneas syndrome 
[3, 8, 11, 15]. It has been shown that treatment with octreo-
tide can reduce sleep apnea indices (respiratory disturbance 
index (RDI)) and tongue volume [3, 16]. The same observa-
tions could be documented with pegvisomant [8]. The effect of 
treatment with SSA, pegvisomant and dopaminergic agonists 
is the result of IGF-I and/or GH-normalization with the con-
sequence of reduced soft tissue swelling of the uvula and the 
tongue volume, which has a major impact of OSA [17]. The 
direct effect of these drugs is less relevant. The study from van 
Haute et al could document that a high prevalence OSA (88%) 
remained in patients with active acromegaly despite previous 
treatment with dopaminergic agonist, as well as after surgery 
Table 2.  Patients With Well-Controlled Acromegaly Treated 
With Somatostatin Analogues, Pegvisomant or in Combination 
After Examination of Polygraphy
Treatments/medications AHI < 5 AHI ≥ 5 P
Age (years) 47 ± 13 61 ± 9 0.037
M/F 9/16 2/2 n.s.
BMI (kg/m2) 30.0 ± 5.7 30.0 ± 3.0 n.s.
Disease duration (years) 12 ± 8 16 ± 1 0.01
AHI 2 ± 2 9 ± 4 0.05
Epworth sleepiness scale score 6 ± 4 4 ± 2 n.s.
IGF-I (µg/L) 187 ± 78 169 ± 30 n.s.
Figure 1. Patients with well-controlled acromegaly treated with soma-
tostatin analogues, pegvisomant or in combination after examination of 
polygraphy. Division in a group apnea-hypnea index (AHI) < 5 and AHI 
≥ 5: mean ± SEM.
Figure 2. Patients with well-controlled acromegaly treated with soma-
tostatin analogues, pegvisomant or in combination after examination of 
polygraphy. Correlation between apne-hypnea index (AHI) and age (P 
= 0.01; r = 0.44).
Table 3.  Treatment of Patients With Well-Controlled After Ex-
amination of Polygraphy
AHI < 5 AHI ≥ 5
Number 25 (87%) 4 (13%)
Previous treatment
  Surgery 19 (76%) 3 (75%)
  Radiation + surgery 6 (24%) 1 (25%)
Current medication
  SSA 9 (36%) 2 (50%)
  Pegvisomant 10 (40%) 1 (25%)
  SSA + pegvisomant 6 (24%) 1 (25%)
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and radiotherapy [14].
In a small cohort of 16 patients from Chemla et al, 11 pa-
tients were well controlled with SSA (n = 2), pegvisomant (n 
= 9) or surgery (n = 5) after a period of 11 months. Seven of 
16 had SAS, and in 4/7, sleep apnea syndrome improved [15]. 
Recently, in a retrospective study, 12 patients with OSA were 
evaluated by polysomnography after a period of 16 months 
with pegvisomant. Seventy-six percent were pre-treated by 
surgery or additional radiation (17%). OSA improved in 6/8 
patients and disappeared in 4/12 [18].
These and other previous studies examined a very heter-
ogenous cohort with small numbers and a relative short period 
of well-controlled acromegaly. It was mentioned in previous 
papers that a longer follow-up to detect later possible improve-
ments in OSA will be needed [10, 11].
For that reason, we performed a cross-sectional multicent-
er study to examine patients with acromegaly, well-controlled 
with SSA and/or pegvisomant over a mean period of 7 years. 
Only 14% had OSA, which was in most of the cases mild to 
moderate. The low Epworth sleepiness score of 5 confirmed 
this low prevalence. OSA correlated with age, but not with 
BMI. This low prevalence is less frequent as in the study of 
Annamalai et al (2013) [10]. They documented a prevalence 
of 39% (9/23) after a period of 24 months treatment with lan-
reotide autogel and well-controlled acromegaly. This higher 
prevalence may be due to a shorter treatment period of 2 ver-
sus 7 years in our study. Moreover, they have included newly 
diagnosed patients with acromegaly in contrast to our group in 
the present study, who was pre-treated with surgery (76%) or 
additional radiation (24%). Another reason for the low preva-
lence may be due to the high percentage of patients treated 
with pegvisomant alone or in addition to SSA (59%).
OSA is a disease of the middle age in non-acromegalic 
population and correlates with age. This fact is similar to our 
observation that the AHI correlated with the age of the patients 
with acromegaly, independent of IGF-I levels. Concerning the 
prevalence of OSA, it may be speculative, whether acromegal-
ics with well-controlled disease assimilate to non-acromegalic 
over time.
In the present study, patients with OSA had a longer dis-
ease duration than patients without OSA. This observation is 
similar to other systemic complications in acromegaly, such as 
cardiomyopathy, arrhythmias and cranio-facial alterations [1, 
19, 20]. The untreated GH and IGF-I excess induces progna-
thism, increases tongue volume and enlarges uvula which nar-
row the upper airway and hence generate signs and symptoms 
of OSA [5, 21, 22].
Therefore, early detection of acromegaly to reduce the 
active disease period is the aim to prevent patients with ac-
romegaly of systemic complications such as OSA [23]. Due 
to the amelioration of treatment by surgery, radiation and suf-
ficient use of SSA and pegvisomant, the prevalence of OSA in 
patients with well-controlled acromegaly is less frequent.
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